News

Teva Partners with Prestige Biopharma for Tuznue® in Europe

Teva Partners with Prestige Biopharma for Tuznue® in Europe

Teva and Prestige Biopharma Forge Partnership for Tuznue®

Teva Pharmaceuticals has secured a license and supply agreement with Prestige Biopharma, focusing on the commercialization of Tuznue®, a biosimilar to the established Herceptin® (trastuzumab). This collaboration marks a significant step in enhancing patient access to treatment options in Europe.

Understanding Tuznue®

Tuznue® is designed to be a cost-effective therapy, showing similar efficacy and safety as its branded counterpart, Herceptin®. It is specifically indicated for patients facing HER2-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic gastric cancer. The European Commission granted marketing authorization for Tuznue®, allowing more patients to benefit from this innovative treatment.

A Collaboration of Expertise

Under the new agreement, Teva will leverage its extensive commercial network to market and distribute Tuznue® across a majority of European countries. Prestige Biopharma will handle the production, ensuring high-quality supply from its state-of-the-art, EU-GMP-certified manufacturing facility, well-equipped for modern biosimilars.

“Our collaboration with Prestige signifies a shared commitment to advancing health care through biosimilars,” said Richard Daniell, Executive Vice President for European Commercial at Teva. “This partnership will unlock new potential for patients in Europe, ensuring they receive vital medications efficiently.”

The Vision of Prestige Biopharma

Lisa Park, CEO of Prestige Biopharma, expressed enthusiasm for the partnership: “Teva’s strong market presence will propel the launch of Tuznue® across Europe, elevating our goal to emerge as a leader in this essential sector. With Teva’s support, we can enhance our pipeline that includes bevacizumab and several other candidates.” This agreement emphasizes a collective effort toward enhancing healthcare access through biosimilars.

Tuznue®: A Boon for Patients

As a biosimilar, Tuznue® aims to replicate the effectiveness of Herceptin® while also offering a more accessible price point, thus opening doors for many patients. The approval signifies an important breakthrough in the biosimilar landscape, allowing for broader access to necessary medications for treating severe health conditions.

About Teva Pharmaceutical Industries

Teva, established over 120 years ago, stands at the forefront of the biopharmaceutical industry. Rooted in a commitment to enhance patient health, Teva integrates innovation within neuroscience, immunology, and complex generics, ensuring they are adept at meeting patient needs globally.

About Prestige Biopharma

Founded in 2015 in Singapore, Prestige Biopharma operates a dedicated GMP manufacturing facility in Korea, which showcases a production capacity of 154,000 liters. The company is actively engaged in developing groundbreaking biosimilars and antibody drugs, aiming for substantial impact in the global biopharmaceutical market.

Frequently Asked Questions

What is Tuznue®?

Tuznue® is a biosimilar to Herceptin® (trastuzumab), approved for treating HER2-positive conditions, such as breast and gastric cancers.

Who are the partners in this agreement?

Teva Pharmaceuticals and Prestige Biopharma are the primary partners in this significant licensing agreement for Tuznue® commercialization.

What markets will Tuznue® be available in?

Tuznue® will be marketed and distributed by Teva across a majority of European markets, enhancing access for patients.

What role does Prestige Biopharma play?

Prestige Biopharma will be responsible for production and supply of Tuznue® using its advanced manufacturing capabilities.

How does this partnership impact patients?

This collaboration will facilitate greater access to effective cancer treatments, aligning with the companies' commitment to improving healthcare outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 135

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 73

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 36

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Healthcare: ShiftMed Enhances Scheduling at UNC Health

Updated Category News Views 389

Introduction to ShiftMed Flex at UNC Health UNC Health is taking a significant step forward by implementing ShiftMed Flex, a transformative solution aimed at enhancing workforce efficiency throughout its network. This innovative AI-driven platform is designed to improve shift participation by better matching healthcare providers' schedules with available shifts,...

Continue Reading
Rivian's Q4 Financial Performance Sparks Investor Optimism

Updated Category News Views 168

Rivian's Strong Financial Performance Rivian Automotive stock has demonstrated significant resilience and growth recently. Investors are keen to understand the factors that are propelling RIVN stock upward. The latest quarterly earnings report has highlighted Rivian’s remarkable performance, which is robust evidence of the company's progress in the competitive electric...

Continue Reading
Purple Biotech's Innovative Advancements with CAPTN-3 Antibody Platform

Updated Category News Views 295

Exciting Developments in Cancer Treatment from Purple Biotech Purple Biotech, a clinical-stage company at the forefront of oncology, has made impressive strides in its novel tri-specific T cell and NK cell engager platform, known as CAPTN-3. This innovative approach demonstrates sustained tumor regression in an in-vivo model of triple-negative breast cancer and showcases...

Continue Reading
Raytron's Thermal Technology Enhances Robotaxi Safety in All Weather

Updated Category News Views 222

Raytron's Innovative Thermal Cameras for Autonomous Driving As advancements in technology reshape our transportation systems, one major player in the field is Raytron, a leader in infrared thermal imaging. A pressing challenge in the rollout of Level 4 (L4) robotaxis is ensuring safe operation in various climatic conditions, especially during extreme weather. With...

Continue Reading
Investors Urged to Join Centene Corporation Class Action Now

Updated Category News Views 116

Centene Corporation Faces Class Action Lawsuit Levi & Korsinsky, LLP has officially notified investors about a class action lawsuit targeting Centene Corporation. This lawsuit may affect shareholders who experienced losses due to alleged securities fraud. Centene Corporation, identified by its ticker CNC, is at the center of this legal action, which has drawn attention...

Continue Reading